{
 "generated": "2026-08-20",
 "note": "Machine mirror of /journal/glp1-trial-index/. '~' marks topline/varying reports; confirm against primary publications.",
 "trials": [
  {
   "trial": "STEP 1",
   "year": 2021,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "obesity, no diabetes",
   "duration": "68 wk",
   "headline": "-14.9% vs -2.4% placebo"
  },
  {
   "trial": "STEP 2",
   "year": 2021,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "obesity + T2D",
   "duration": "68 wk",
   "headline": "-9.6% vs -3.4%"
  },
  {
   "trial": "STEP 3",
   "year": 2021,
   "agent_design": "semaglutide 2.4 + intensive behavioral therapy",
   "population": "obesity",
   "duration": "68 wk",
   "headline": "-16.0% vs -5.7%"
  },
  {
   "trial": "STEP 4",
   "year": 2021,
   "agent_design": "semaglutide 2.4, randomized withdrawal",
   "population": "wk-20 responders",
   "duration": "wk 20-68",
   "headline": "continue -7.9% further vs +6.9% regain"
  },
  {
   "trial": "STEP 5",
   "year": 2022,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "obesity",
   "duration": "104 wk",
   "headline": "-15.2% vs -2.6%"
  },
  {
   "trial": "STEP 8",
   "year": 2022,
   "agent_design": "semaglutide 2.4 vs liraglutide 3.0 (head-to-head)",
   "population": "obesity",
   "duration": "68 wk",
   "headline": "-15.8% vs -6.4%"
  },
  {
   "trial": "STEP TEENS",
   "year": 2022,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "adolescents 12-17",
   "duration": "68 wk",
   "headline": "BMI ~-16% vs ~+0.6%"
  },
  {
   "trial": "STEP-HFpEF",
   "year": 2023,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "obesity-related HFpEF",
   "duration": "52 wk",
   "headline": "KCCQ +16.6 vs +8.7; weight -13.3%"
  },
  {
   "trial": "OASIS 1",
   "year": 2023,
   "agent_design": "oral semaglutide 50 mg daily",
   "population": "obesity",
   "duration": "68 wk",
   "headline": "-15.1% vs -2.4%"
  },
  {
   "trial": "SELECT",
   "year": 2023,
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "CVD + overweight/obesity, no diabetes",
   "duration": "~40 mo",
   "headline": "MACE -20% (HR 0.80)"
  },
  {
   "trial": "FLOW",
   "year": 2024,
   "agent_design": "semaglutide 1.0 mg weekly",
   "population": "T2D + CKD",
   "duration": "stopped early",
   "headline": "kidney events -24% (HR 0.76)"
  },
  {
   "trial": "ESSENCE part 1",
   "year": "2024-25",
   "agent_design": "semaglutide 2.4 mg weekly",
   "population": "MASH with fibrosis",
   "duration": "72 wk",
   "headline": "MASH resolution ~63% vs ~34%"
  },
  {
   "trial": "SUSTAIN-6",
   "year": 2016,
   "agent_design": "semaglutide (T2D doses)",
   "population": "T2D high CV risk",
   "duration": "104 wk",
   "headline": "MACE HR 0.74"
  },
  {
   "trial": "SCALE Obesity",
   "year": 2015,
   "agent_design": "liraglutide 3.0 mg daily",
   "population": "obesity",
   "duration": "56 wk",
   "headline": "-8.0% vs -2.6%"
  },
  {
   "trial": "LEADER",
   "year": 2016,
   "agent_design": "liraglutide (T2D doses)",
   "population": "T2D high CV risk",
   "duration": "~3.8 yr",
   "headline": "MACE HR 0.87"
  },
  {
   "trial": "SURMOUNT-1",
   "year": 2022,
   "agent_design": "tirzepatide 5/10/15 mg weekly",
   "population": "obesity, no diabetes",
   "duration": "72 wk",
   "headline": "-15.0/-19.5/-20.9% vs -3.1%"
  },
  {
   "trial": "SURMOUNT-2",
   "year": 2023,
   "agent_design": "tirzepatide 10/15 mg weekly",
   "population": "obesity + T2D",
   "duration": "72 wk",
   "headline": "-12.8/-14.7% vs -3.2%"
  },
  {
   "trial": "SURMOUNT-3",
   "year": 2023,
   "agent_design": "tirzepatide after lifestyle lead-in",
   "population": "obesity",
   "duration": "72 wk",
   "headline": "further ~-18% vs ~+2.5%"
  },
  {
   "trial": "SURMOUNT-4",
   "year": 2024,
   "agent_design": "tirzepatide, randomized withdrawal",
   "population": "wk-36 responders",
   "duration": "wk 36-88",
   "headline": "continue -5.5% further vs +14.0% regain"
  },
  {
   "trial": "SURMOUNT-5",
   "year": 2025,
   "agent_design": "tirzepatide vs semaglutide 2.4 (head-to-head)",
   "population": "obesity",
   "duration": "72 wk",
   "headline": "-20.2% vs -13.7%"
  },
  {
   "trial": "SURMOUNT-OSA",
   "year": 2024,
   "agent_design": "tirzepatide max tolerated",
   "population": "obesity + moderate-severe OSA",
   "duration": "52 wk",
   "headline": "AHI -25.3 / -29.3 events/hr"
  },
  {
   "trial": "SURPASS-2",
   "year": 2021,
   "agent_design": "tirzepatide vs semaglutide 1.0 (T2D doses)",
   "population": "T2D",
   "duration": "40 wk",
   "headline": "greater A1c and weight reduction"
  },
  {
   "trial": "REWIND",
   "year": 2019,
   "agent_design": "dulaglutide 1.5 mg weekly",
   "population": "T2D broad risk",
   "duration": "~5.4 yr",
   "headline": "MACE HR 0.88"
  },
  {
   "trial": "REDEFINE-1",
   "year": 2024,
   "agent_design": "CagriSema weekly",
   "population": "obesity",
   "duration": "68 wk",
   "headline": "~-22.7% (topline)"
  },
  {
   "trial": "Retatrutide phase 2",
   "year": 2023,
   "agent_design": "retatrutide (GLP-1/GIP/glucagon)",
   "population": "obesity",
   "duration": "48 wk",
   "headline": "~-24.2% top dose"
  },
  {
   "trial": "ATTAIN-1",
   "year": 2025,
   "agent_design": "orforglipron daily oral",
   "population": "obesity",
   "duration": "72 wk",
   "headline": "~-11-12% top dose (topline)"
  },
  {
   "trial": "MariTide phase 2",
   "year": 2024,
   "agent_design": "maridebart cafraglutide monthly",
   "population": "obesity +/- T2D",
   "duration": "52 wk",
   "headline": "~-20% (phase 2)"
  }
 ]
}